Jubilant Pharmova Stock Screener | Share Price & Fundamental Analysis

JUBLPHARMA Pharmaceuticals
Screen Jubilant Pharmova share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1079.10
▲ 8.50 (0.79%)
2026-01-06 00:00:00
Share Price BSE
₹1080.80
▲ 10.60 (0.99%)
2026-01-06 00:00:00
Market Cap ₹16,577.98 Cr.
P/B Ratio 2.54
EPS (TTM) ₹52.99
Dividend Yield 0.48%
Debt to Equity 0.55
52W High ₹1236.30
52W Low ₹828.10
Operating Margin 17.00%
Profit Margin 7.83%
Revenue (TTM) ₹1,928.00
EBITDA ₹341.00
Net Income ₹151.00
Total Assets ₹12,756.00
Total Equity ₹6,239.00

Jubilant Pharmova Share Price History - Stock Screener Chart

Screen JUBLPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.

Jubilant Pharmova Company Profile - Fundamental Screener

Screen Jubilant Pharmova company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for JUBLPHARMA shares.
Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
Chairperson/CEO Shyam S Bhartia
ISIN INE700A01033

Jubilant Pharmova Balance Sheet Screener - Fundamental Analysis

Fair Value Analysis
Screen JUBLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Assets
Total Assets 12,756 11,549 11,157 9,991 8,918 12,522 11,469 9,618 9,041 8,824
Current Assets 3,577 3,876 3,762 3,509 2,953 5,038 4,585 3,190 2,948 2,875
Fixed Assets 5,176 5,091 5,183 4,871 4,609 6,340 5,648 5,401 5,107 5,104
Liabilities
Total Liabilities 12,756 11,549 11,157 9,991 8,918 12,522 11,469 9,618 9,041 8,824
Current Liabilities 4,353 4,238 3,993 3,083 3,128 4,299 4,570 3,578 3,968 3,432
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 6,239 5,421 5,392 5,316 4,742 5,604 4,809 4,035 3,389 2,928
Share Capital 16 16 16 16 16 16 16 16 16 16
Reserves & Surplus 6,239 5,418 5,383 5,303 4,726 5,588 4,793 4,071 3,421 2,951
Screen JUBLPHARMA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept 2022-Dec
Revenue 1,928 1,891 1,968 1,764 2,130 1,764 1,823 1,682 1,575 1,686 1,714 1,513 1,452 1,598 1,543
Expenses 1,587 1,611 1,631 1,656 1,480 1,477 1,554 1,459 1,419 1,439 1,459 1,280 1,259 1,440 1,408
EBITDA 341 280 337 108 650 287 269 223 156 247 255 233 192 158 134
Operating Profit % 17.00% 14.00% 17.00% 5.00% 14.00% 15.00% 14.00% 12.00% 9.00% 14.00% 12.00% 15.00% 13.00% 9.00% 8.00%
Depreciation 95 98 105 101 91 91 91 271 90 97 95 101 95 94 94
Interest 53 49 50 73 71 61 56 56 62 66 71 40 40 42 51
Profit Before Tax 206 154 190 -54 500 144 131 -86 25 98 101 106 69 36 9
Tax 55 52 70 8 18 42 30 14 19 36 35 47 22 32 25
Net Profit 151 103 120 -62 482 103 101 -101 6 62 66 59 47 5 -16
EPS 9.71 6.49 7.59 -3.69 30.44 6.47 6.37 -6.15 0.40 3.94 4.22 3.74 2.96 0.34 -0.98

Jubilant Pharmova Cash Flow Screener - Liquidity Fundamentals

Screen JUBLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March
Operating Activities 1,072 971 661 838 1,784 1,543 1,122 1,303 1,269 1,099
Investing Activities 513 -596 -474 -323 -727 -267 -1,018 -614 -465 -309
Financing Activities -1,453 -433 -157 -33 -1,709 -1,050 657 -901 -686 -843
Net Cash Flow 132 -58 30 482 -652 225 761 -212 117 -52
Screen JUBLPHARMA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar
Promoter Holding 50.68% 47.68% 47.68% 50.68% 50.68% 50.68% 50.68% 50.68%
FII Holding 17.22% 17.40% 16.57% 19.06% 19.49% 17.94% 16.96% 0.00%
DII Holding 7.05% 9.53% 10.52% 3.78% 4.07% 5.66% 6.98% 0.40%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.24%
Public Holding 17.75% 17.97% 18.02% 18.71% 17.79% 18.09% 18.09% 18.69%
Other Holding 7.31% 7.42% 7.22% 7.77% 7.97% 7.63% 7.30% 28.98%
Shareholder Count 96,526 99,673 93,336 92,264 81,992 89,456 102,442 97,935

Jubilant Pharmova Dividend Screener - Share Yield Analysis

Screen JUBLPHARMA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Period Dividend Per Share Dividend Yield
2025-March ₹5.00 0.47%
2024-March ₹5.00 0.56%
2023-March ₹5.00 0.88%
2022-March ₹5.00 1.79%
2021-March ₹5.00 1.29%
2020-March ₹5.00 0.73%
2019-March ₹4.50 1.81%
2018-March ₹3.00 0.45%
2017-March ₹3.00 0.36%
2016-March ₹0.00 0.00%

Jubilant Pharmova Index Membership - Market Screener Classification

Screen JUBLPHARMA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.

Jubilant Pharmova Market Events Screener - Corporate Actions

Screen JUBLPHARMA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
Announcement Date Record Date Event Type Information Price Impact
2025-10-31 2025-10-31 Quarterly Result Announcement NA 1.90%
2025-08-29 2025-08-29 Annual General Meeting NA -7.13%
2025-07-29 2025-07-29 Quarterly Result Announcement NA -2.98%
2025-07-25 2025-07-25 Dividend ₹ 5.00 /share 29.75%
2025-05-16 2025-05-16 Quarterly Result Announcement NA 1.03%
2025-01-31 2025-01-31 Quarterly Result Announcement NA 1.84%
2024-10-25 2024-10-25 Quarterly Result Announcement NA -9.79%
2024-08-30 2024-08-30 Annual General Meeting NA 8.43%
2024-08-02 2024-08-02 Dividend ₹ 5.00 /share 23.06%
2023-08-10 2023-08-10 Dividend ₹ 5.00 /share 11.53%
2022-08-11 2022-08-12 Dividend ₹ 5.00 /share -11.02%
2021-08-05 2021-08-06 Dividend ₹ 5.00 /share -22.02%
2021-02-01 2021-02-01 Change Of Name NA 0.00%

Jubilant Pharmova Competitors Screener - Peer Comparison

Screen JUBLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 412,734 39.30 54,729 9.71% 10,980 39.06
Divis Laboratories 168,851 68.25 9,712 18.67% 2,191 44.96
Torrent Pharmaceuticals 129,357 59.98 11,539 6.99% 1,911 59.35
Cipla 120,557 22.21 28,410 7.12% 5,291 42.76
Dr Reddys Laboratories 105,645 18.46 33,741 16.73% 5,725 49.97
Lupin 95,023 21.85 22,910 13.74% 3,306 50.10
Zydus Life Science 90,707 18.09 23,511 18.55% 4,615 34.06
Mankind Pharma 88,846 50.78 12,744 20.90% 2,007 40.67
Aurobindo Pharma 68,901 20.36 32,346 9.43% 3,484 46.33
Alkem Laboratories 65,390 27.28 13,458 3.70% 2,216 37.45

Jubilant Pharmova Company Announcements - News Screener

Screen JUBLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-01-07 Announcement under Regulation 30 (LODR)-Acquisition View
2026-01-06 Closure of Trading Window View
2026-01-04 Jubilant Generics Limited - Order Passed By The Assistant Commissioner Central GST Division Roorkee View
2025-12-05 Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- Receipt Of Adjudication Order_GST View
2025-12-02 Report On Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares View
2025-12-02 Appointment Of Mr. Daniel J. OConnor As CEO Of Jubilant Therapeutics Inc. View
2025-11-28 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2025-11-08 Submission Of Communication Email Sent To Shareholders Whose Dividend(S) Remains Unpaid Pursuant To "Saksham Niveshak - 100 Days Campaign" View
2025-11-04 USFDA Communication Montreal Canada View
2025-11-01 Announcement under Regulation 30 (LODR)-Newspaper Publication View
2025-10-31 Announcement under Regulation 30 (LODR)-Press Release / Media Release View
2025-10-31 Approval For Grant Of Stock Options/Rsus View
2025-10-31 Un-Audited Standalone & Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025 View
2025-10-31 Board Meeting Outcome for Meeting Held On October 31 2025 View
2025-10-27 Letter To Shareholders Whose KYC Is Not Updated View
2025-10-14 Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 View
2025-10-10 Press Release Pertaining To The Launch Of New High-Speed Isolator Based Line At Its Spokane Manufacturing Facility In The US By Jubilant Hollisterstier LLC USA A Wholly-Owned Subsidiary Of The Company View
2025-10-08 Submission Of Communication Email Sent To Shareholders Whose Dividend(S) Remains Unpaid Pursuant To "Saksham Niveshak - 100 Days Campaign" View
2025-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 View
2025-10-01 Announcement under Regulation 30 (LODR)-Newspaper Publication View